HPRA Drug Safety Newsletter Edition 90

Download: hpra-drug-safety-newsletter-edition-90.pdf 259 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates to support the safe and appropriate use of the following medicines:

Rivaroxaban (Xarelto) - Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial.

Insulin-containing products - Risk of medication errors associated with extraction of insulin from pre-filled pens and cartridges for reusable pens.

Hydrochlorothiazide - Risk of non-melanoma skin cancer (NMSC).

Dolutegravir - Neural tube defects reported in infants born to women exposed at the time of conception.

Direct Healthcare Profession Communications published on the HPRA website since the last Drug Safety Newsletter.

« Back